Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA
Scleroderma Program, Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA.
Ann Rheum Dis. 2020 Mar;79(3):379-386. doi: 10.1136/annrheumdis-2019-215894. Epub 2019 Nov 25.
Determine global skin transcriptome patterns of early diffuse systemic sclerosis (SSc) and how they differ from later disease.
Skin biopsy RNA from 48 patients in the Prospective Registry for Early Systemic Sclerosis (PRESS) cohort (mean disease duration 1.3 years) and 33 matched healthy controls was examined by next-generation RNA sequencing. Data were analysed for cell type-specific signatures and compared with similarly obtained data from 55 previously biopsied patients in Genetics versus Environment in Scleroderma Outcomes Study cohort with longer disease duration (mean 7.4 years) and their matched controls. Correlations with histological features and clinical course were also evaluated.
SSc patients in PRESS had a high prevalence of M2 (96%) and M1 (94%) macrophage and CD8 T cell (65%), CD4 T cell (60%) and B cell (69%) signatures. Immunohistochemical staining of immune cell markers correlated with the gene expression-based immune cell signatures. The prevalence of immune cell signatures in early diffuse SSc patients was higher than in patients with longer disease duration. In the multivariable model, adaptive immune cell signatures were significantly associated with shorter disease duration, while fibroblast and macrophage cell type signatures were associated with higher modified Rodnan Skin Score (mRSS). Immune cell signatures also correlated with skin thickness progression rate prior to biopsy, but did not predict subsequent mRSS progression.
Skin in early diffuse SSc has prominent innate and adaptive immune cell signatures. As a prominently affected end organ, these signatures reflect the preceding rate of disease progression. These findings could have implications in understanding SSc pathogenesis and clinical trial design.
确定早期弥漫性系统性硬化症(SSc)的全球皮肤转录组模式,以及它们与后期疾病的不同之处。
对前瞻性早期系统性硬化症登记处(PRESS)队列中 48 例患者(平均疾病持续时间为 1.3 年)和 33 例匹配的健康对照者的皮肤活检 RNA 进行下一代 RNA 测序。分析细胞类型特异性特征,并与先前在遗传学与环境对硬皮病结局研究队列中同样获得的 55 例具有较长疾病持续时间(平均 7.4 年)和匹配对照者的活检数据进行比较。还评估了与组织学特征和临床病程的相关性。
PRESS 中的 SSc 患者具有高比例的 M2(96%)和 M1(94%)巨噬细胞和 CD8 T 细胞(65%)、CD4 T 细胞(60%)和 B 细胞(69%)特征。免疫细胞标志物的免疫组织化学染色与基于基因表达的免疫细胞特征相关。早期弥漫性 SSc 患者的免疫细胞特征患病率高于疾病持续时间较长的患者。在多变量模型中,适应性免疫细胞特征与疾病持续时间较短显著相关,而成纤维细胞和巨噬细胞细胞类型特征与改良 Rodnan 皮肤评分(mRSS)较高相关。免疫细胞特征也与活检前的皮肤厚度进展率相关,但不能预测随后的 mRSS 进展。
早期弥漫性 SSc 的皮肤具有显著的先天和适应性免疫细胞特征。作为一个主要受累的终末器官,这些特征反映了疾病进展的先前速度。这些发现可能对理解 SSc 的发病机制和临床试验设计具有重要意义。